Squarepoint Ops LLC purchased a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,499 shares of the company’s stock, valued at approximately $74,000.
A number of other large investors have also added to or reduced their stakes in MYO. AIGH Capital Management LLC grew its position in Myomo by 21.7% during the fourth quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock worth $21,777,000 after buying an additional 602,719 shares in the last quarter. Portolan Capital Management LLC bought a new stake in Myomo during the fourth quarter worth $2,446,000. Manatuck Hill Partners LLC bought a new stake in Myomo during the fourth quarter worth $1,582,000. Aristides Capital LLC bought a new stake in Myomo during the fourth quarter worth $1,288,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Myomo during the fourth quarter worth $1,288,000. Institutional investors and hedge funds own 44.99% of the company’s stock.
Myomo Stock Down 3.0%
Shares of MYO opened at $2.88 on Wednesday. Myomo, Inc. has a 52 week low of $2.76 and a 52 week high of $7.17. The company has a market cap of $87.12 million, a PE ratio of -12.52 and a beta of 1.68. The firm has a fifty day moving average price of $3.88.
Insider Activity
Analyst Upgrades and Downgrades
Several research firms have weighed in on MYO. Alliance Global Partners restated a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. HC Wainwright upped their target price on Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research note on Wednesday, March 12th. Craig Hallum cut their target price on Myomo from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Ascendiant Capital Markets upped their target price on Myomo from $11.00 to $11.50 and gave the stock a “buy” rating in a research note on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $9.63.
Get Our Latest Analysis on MYO
About Myomo
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
Further Reading
- Five stocks we like better than Myomo
- Insider Trades May Not Tell You What You Think
- AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
- Investing in the High PE Growth Stocks
- Casey’s Surges on Strong Q4, More Gains Likely Ahead
- Asset Allocation Strategies in Volatile Markets
- Government Mandate Sends eVTOL Stocks Flying
Want to see what other hedge funds are holding MYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myomo, Inc. (NYSEAMERICAN:MYO – Free Report).
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.